Eirion Therapeutics

ET-01 Topical Botulinum for Lateral Canthal Lines (Crow’s Feet) and Primary Axillary Hyperhidrosis

Modern Aesthetics magazine interviewed Eirion Therapeutics Chairman, CEO, and President Jon Edelson about the company’s pipeline for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair graying.

Eirion Therapeutics announced that the first participants had been dosed in a Phase 1/2 trial of AI-09 for glabellar wrinkles.

Eirion Therapeutics enrolled the first participant in a Phase 1 trial evaluating the safety of topical ET-02 for androgenic alopecia. The double-blind, placebo-controlled study evaluates once-daily treatment over 28 days.

Eirion Therapeutics reported successful Phase 1–2 trial results for its next-generation liquid injectable neuromodulator for moderate to severe glabellar wrinkles and planned to present an update at the 2024 Medical Aesthetic Injectable Summit.

Eirion Therapeutics announced that CEO and President Jon Edelson would present first-in-human trial results for topical ET-02 at the 2025 American Academy of Dermatology Innovation Academy.

The company has had Barry Kurokawa on its board since its inception. He is CEO and co-founder of Dianomi Therapeutics and has been a healthcare-focused professional investor for over 25 years.

Carter Meyer, JD has served on the company's board since inception. Carter Meyer, JD is founder and managing partner of View Ventures, which invests in medical and health technologies, and was CEO of SHD Management, LLC for 14 years.

The page identifies a senior vice president of clinical operations.

The company has had Klaus Theobald as chief research and development officer since its inception in January 2016. He previously led R&D at Anterios and CollaGenex.